Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 💯78

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,008 result(s) found for: 💯78. Displaying page 1 of 51.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-002460-26 Sponsor Protocol Number: OP/2006/2262 Start Date*: 2006-07-21
    Sponsor Name:UBHT
    Full Title: A trial of intranasal remifentanil for painful ophthalmic procedures.
    Medical condition: Painful ophthalmic procedures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013342-92 Sponsor Protocol Number: DSE-OLM-01-09 Start Date*: 2010-06-08
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM)
    Medical condition: Essential hypertension in subjects with documented carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001711-23 Sponsor Protocol Number: ET19-084 Start Date*: 2020-02-03
    Sponsor Name:Centre Léon Bérard
    Full Title: CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-meta...
    Medical condition: Breast adenocarcinoma treated with post-operative radiotherapy Post-operative breast cancer radiotherapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000678-41 Sponsor Protocol Number: ET19-006 Start Date*: 2019-05-13
    Sponsor Name:Centre Léon Bérard
    Full Title: CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases
    Medical condition: Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001430-19 Sponsor Protocol Number: ET21-084 Start Date*: 2021-07-08
    Sponsor Name: Centre Léon Berard
    Full Title: GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in ...
    Medical condition: locally advanced or metastatic Gastrointestinal Stromal Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002821-28 Sponsor Protocol Number: ET20-128 Start Date*: 2020-12-24
    Sponsor Name:Centre Léon Bérard
    Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o...
    Medical condition: Metastatic or unresectable advanced rare sarcomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000602-10 Sponsor Protocol Number: SNT-III-012 Start Date*: 2016-11-17
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Ste...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007938-21 Sponsor Protocol Number: 1245.24 Start Date*: 2009-03-30
    Sponsor Name:Boehringer Ingelheim GmbH&Co KG
    Full Title: A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients.
    Medical condition: Diabetes type 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) SE (Completed) DE (Completed) EE (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) LT (Completed) HU (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006545-36 Sponsor Protocol Number: B1000-PMO-03-G-02 Start Date*: 2022-05-18
    Sponsor Name:Biocon Biologics UK Limited
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia in Postmenopausal Women with O...
    Medical condition: Postmenopausal women diagnosed with osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005755-20 Sponsor Protocol Number: ALZ-801-AD301 Start Date*: 2021-06-21
    Sponsor Name:Alzheon, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype
    Medical condition: Early Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004158-10 Sponsor Protocol Number: ALMED-07-C2-012 Start Date*: 2008-04-17
    Sponsor Name:AIR LIQUIDE
    Full Title: A single site, exploratory, phase I / II, randomised trial comparing the effect of Helium/Oxygen mixtures (He/O2 78:22 and He/O2 65:35) to medical air on pulmonary function in moderate / severe ast...
    Medical condition: - healthy volunteers, - moderate and severe persistent asthmatic patients, - moderate and severe COPD patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004115-12 Sponsor Protocol Number: 1002-050 Start Date*: 2017-05-17
    Sponsor Name:Esperion Therapeutics, Inc.
    Full Title: A Multicenter Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg
    Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    21.0 100000004861 10020667 Hyperlipidemia LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003994-80 Sponsor Protocol Number: ET18-270 Start Date*: 2019-10-03
    Sponsor Name:Centre Léon Bérard
    Full Title: A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases
    Medical condition: Brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000130-20 Sponsor Protocol Number: R3918-PNH-1868 Start Date*: 2020-04-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria
    Medical condition: Paroxysmal nocturnal hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004926-26 Sponsor Protocol Number: PRV-031-001 Start Date*: 2019-11-21
    Sponsor Name:Provention Bio, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in ...
    Medical condition: Type 1 Diabetes (T1D)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) FR (Completed) FI (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-006017-38 Sponsor Protocol Number: RGB-14-101 Start Date*: 2021-07-13
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) CZ (Completed) HU (Completed) BG (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024194-39 Sponsor Protocol Number: BO21005 Start Date*: 2011-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: ENSAYO DE FASE III, MULTICÉNTRICO, ABIERTO Y ALEATORIZADO PARA COMPARAR LA EFICACIA DE GA101 (RO5072759) EN COMBINACIÓN CON CHOP (G-CHOP) FRENTE A RITUXIMAB Y CHOP (R-CHOP) EN PACIENTES CON LINFOMA...
    Medical condition: PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Pacientes CD20+ con linfoma difuso de celulas B grandes que no han sido previamente tratados
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012819 Diffuse large B-cell lymphomas HLT
    12.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SK (Completed) CZ (Completed) HU (Completed) IT (Completed) DE (Completed) AT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005994-79 Sponsor Protocol Number: 3133K1-3000-WW Start Date*: 2008-05-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...
    Medical condition: Enfermedad de Alzheimer Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001055-40 Sponsor Protocol Number: 111-209 Start Date*: 2020-07-29
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A randomized, controlled, open-label clinical trial with an open-label extension to investigate the safety of BMN 111 in infants and young children with achondroplasia at risk of requiring cervicom...
    Medical condition: achondroplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004653-29 Sponsor Protocol Number: CIGE025A2432 Start Date*: 2008-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 05:31:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA